Eboo Pharmaceuticals Inc is categorized under Commercial Biotechnical Research in Durham, NC and active since 2012.
Eboo Pharmaceuticals Inc was established in 2012, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Robert Mcnutt at the company’s single location by writing to 301 Dunhill Drive, Durham, North Carolina NC 27713 or by phoning (919) 361-5452. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Eboo Pharmaceuticals Inc |
| Contact Person: | Robert Mcnutt |
| Address: | 301 Dunhill Drive, Durham, North Carolina 27713 |
| Phone Number: | (919) 361-5452 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Eboo Pharmaceuticals Inc was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Robert Mcnutt for inquiries that concern Eboo Pharmaceuticals Inc by calling the company number (919) 361-5452, as your correspondence is most welcome. Additionally, the physical location of the single location of Eboo Pharmaceuticals Inc can be found at the coordinates 35.916249,-78.937579 as well as the street address 301 Dunhill Drive in Durham, North Carolina 27713.
For its online presence, you may visit Eboo Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.